
Monopar Therapeutics (MNPR) Stock Forecast & Price Target
Monopar Therapeutics (MNPR) Analyst Ratings
Bulls say
Monopar Therapeutics is viewed favorably because ALXN1840 has a compelling regulatory profile, with positive Phase 3 efficacy data, long-term safety findings, and analyses suggesting copper is being effectively excreted rather than redistributed. The rolling NDA submission initiated in July, together with FDA constructiveness, rare disease guidance, and the potential for a Priority Review Voucher, improves the path to approval while cash of about $129M to $134.3M supports operations through at least March 31, 2028 or YE27. Beyond Wilson disease, the MNPR-101 radiopharmaceutical platform adds optionality in oncology, supporting a substantial unmet-need and commercial opportunity thesis.
Bears say
Monopar Therapeutics is burdened by substantial clinical and regulatory execution risk, as its pipeline remains dependent on proving statistical and clinical benefit in late-stage and early-stage programs such as ALXN1840, MNPR-101-Zr, MNPR-101-Lu, and MNPR-101-Ac. The company also faces a difficult competitive backdrop in Wilson disease, where multiple therapies are already commercialized or in development, potentially limiting adoption even if approval is achieved and making reimbursement and physician switching behavior major obstacles to revenue generation. Given its single-segment, development-stage profile and need for future partnerships or financings, the business remains exposed to dilution, capital constraints, and the possibility that regulatory requirements or negative trial outcomes could derail value creation.
This aggregate rating is based on analysts' research of Monopar Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Monopar Therapeutics (MNPR) Analyst Forecast & Price Prediction
Start investing in Monopar Therapeutics (MNPR)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Monopar Therapeutics (MNPR) Forecast
Monopar Therapeutics (MNPR) Analyst Forecast & Price Prediction
Start investing in Monopar Therapeutics (MNPR)
Order type
Buy in
Order amount
Est. shares
0 shares